Evidence map›Paper›PMID 32368625›Full record

ArticleClinical and translational radiation oncology2020

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report.

Pierluigi Bonomo, Sara Lucidi, Isacco Desideri, Vieri Scotti, Marta Casati, Annarita Palomba, Cinzia Ciabatti, Pietro Garlatti, Daniela Massi, Oreste Gallo and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pierluigi BonomoRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Sara LucidiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Isacco DesideriRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Vieri ScottiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Marta CasatiMedical Physics, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Annarita PalombaSection of Pathological Anatomy, Department of Health Sciences, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Cinzia CiabattiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Pietro GarlattiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Daniela MassiSection of Pathological Anatomy, Department of Health Sciences, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Oreste GalloDepartment of Otolaryngology - Head and Neck Surgery, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Lorenzo LiviRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) represent a recently introduced class of agents active in head and neck squamous cell carcinoma (HNSCC). For a subgroup of patients with recurrent or metastatic disease, long-term benefit can be achieved: maintaining a sustained response to immunotherapy is therefore a critical factor for its efficacy at an individual level. In analogy to targeted agents, a limited pattern of progression, or "oligoprogression", can occur. For locally recurrent HNSCC, the potential biologic interplay between the efficacy of ICIs and the design of radiation fields chosen for primary treatment is currently unknown. Here, we report on a patient who presented two subsequent oligoprogressions successfully treated with re-irradiation without interrupting Nivolumab. Both oligoprogressive lesions developed in previously unirradiated areas. We hypothesize the existence of a synergistic effect with optimal spatial cooperation between ICIs and re-irradiation for oligoprogressive disease under immunotherapy.

Indexed as

Head and neck cancerImmunotherapyIntensity modulated radiotherapyNivolumabOligoprogressionRe-irradiation

Identifiers

PMID32368625
PMCPMC7186263
OpenAlexW3016985199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.